Induction of REV and TAT specific cytotoxic T-cells for preventi

Details Induction of REV and TAT specific cytotoxic T-cells for preventi Induction of REV and TAT specific cytotoxic T-cells for preventi

1996-10-18

2000-02-15

Park, Hankyel

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

536 2372, 53038875, A61K 3921, C07H 2104, C07K 1600

Patent

active

06024965&

ABSTRACT:
The presence of cytotoxic T-cells to the Rev and/or Tat protein in samples from a subject infected with immunodeficiency virus, particularly HIV in humans, is an indication of a stable disease condition and a favourable prognosis of lack of progression to disease. Immunogenic compositions containing at least one cytotoxic T-cell epitope of the Rev and/or Tat protein of an immunodeficiency virus, particularly HIV, or a vector encoding the T-cell epitope, may be used to prevent infection by disease caused by the immunodeficiency virus, by stimulating, in the host, a specific cytotoxic T-cell response specific for the respective Rev and/or Tat proteins.

REFERENCES:
patent: 5336758 (1994-08-01), Berzofsky et al.
patent: 5439809 (1995-08-01), Haynes et al.
Choppin J. et al., HLA-binding regions of HIV-1 proteins: II. A systematic study of viral proteins, J. Immun. 147:575-583, Jul. 1991.
M. R. Klein, F. Miedema, Trends in Microbiology 3, 386 (1995).
I. P.M. Keet et al, AIDS 7, 51 (1993).
B. F. Haynes, G. Pantaleo, A.S. Fauci, Science 271, 324 (1996).
D. F. Nixon et al., Nature 336, 484 (1988).
B. D. Walker et al, Science 240, 64 (1988).
F. Buseyne et al., J. Virol. 67. 694 (1993).
Y. Riviere et al, J. Virol. 63, 2270 (1989).
R. A. Koup et al, Blood 73, 1909 (1989).
R.P. Johnson, B.D. Walker, Curr. Top Microbiol. Immunol. 189, 35 (1994).
S. Lamhamedi-Cherradi et al, AIDS 6, 1249 (1992).
S. Lamhamedi-Cherradi et al, AIDS 9, 421 (1995).
Y. Riviere, M. N. Robertson, F. Buseyne, Curr. Top Microbiol. Immunol.189, 65 (1994).
C. Rinaldo et al. J. Virol 69, 5838 (1995).
A. Carmichael, X. Jin, P Sissons, I Borysiewicz, J. Exp. Med. 177, 249 (1993).
R. A. Koup et al., Journal of Virology 68, 4650 (1994).
M. R. Klein et al, J. Exp. Med. 181, 1365 (1995).
A M. Geretti et al, J. Inf. Dis. 174, 34 (1996).
J. W. Mellors, et al, Science 272, 1167 (1996).
S. Jurriaans, et al, Virol.204, 223 (1994); E. Hogervorst, et al, J. Infect. Dis. 171, 811 (1995); J.W. Mellors, et al, Ann. Intern. Med. 122, 573 (1995); D.R. Henrard, et al, JAMA 274, 554 (1995); K. Sasela, S.E. Stevens, P. Rubinstein, P.E. Taylor, D. Baltimore, Ann. of Intern. Med. 123, 641 (1995).
C. A. van Baalen, et al, AIDS 7, 781 (1993).
B. Culmann-Penciolelli el al, J Virol. 69, 618 (1995).
B. Culmann et al, Eur. J. Immunol. 19, 2382 (1989).
T. Seshamma, O. Bagasra, D. Trono, D. Baltimore, R. J. Pomerantz, Proc. Natl. Acad. Sci. USA, 89, pp. 10663-10667, (1992).
J. Embreston et al. Nature 359 (1993).
T. Hope, R. J. Pomerantz, Curr Top Microbiol. Immunol. 193, 91 (1995).
A. Ranki, A. Lagerstedt, V. Ovod, E. Aavik, K. J. Krohn, Arch Virol. 139, 365 (1994).
V. Blazevic, A. Ranki, K. J. E. Krohn. AIDS Res. Hum. Retroviruses 11, 1335 (1995).
R. M. Zinkernagel, A. Althage, J. Exp. Med. 145, 644 (1977).
Ulmer et al., (1993) Curr. Opinion Invest. Drugs. 2 (9): 983-989.
Hope T., Pomerantz R.J., Current topics in Microbiology and Immunology 193: 91-105, 1995.
Gayner R.B 1995, Current Topics in Microbiology and Immunology 193: 51-77.
Moss B., Science, vol. 252, pp. 1662-1667 (Jun., 1991).
D. Baxby et al., Vaccine vol. 10, Issue 1, 1992.
E. Gonczol et al, Vaccine, vol. 13, No. 12, pp. 1080-1085, 1995.
Jean-Lue Imler, Vaccine vol. 13, No. 13, pp. 1143-1151, 1995.
M.B. Sztein et al., The Journal of Immunology, 1995, 155: pp. 3987-3993.
A. Aldovini et al., Nature (1991), vol. 351: 479-482.
J.W. Shiver et al., Annals New York Academy of Sciences, pp. 198-208, 1995.
S.K. Chai et al, The Journal of Immunology, vol. 149:2385-2390, No. 7, Oct. 1, 1992.
J.P. Sauzet et al., Vaccine, Vo.. 13, No. 14, pp. 1339-1345, 1995.
F. Zhou et al., The Journal of Immunology, vol. 149, 1599-1604, No. 5, Sep. 1, 1992.
H. Takahashi et al., Nature, vol. 344:873-875, Apr. 26, 1990.
Voge et al., Vaccine Design, Ed. Powell et al, 1995, chapter 7, pp. 141-228.
A. Moore et al., Vaccine, vol. 13, No. 18, pp. 1741-1749, 1995.
Sally E. Adams, Vaccine Research, vol. 2: 163-172, No. 3, 1993.

Affiliated with

Also associated with

Rating

Induction of REV and TAT specific cytotoxic T-cells for preventi does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Induction of REV and TAT specific cytotoxic T-cells for preventi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Induction of REV and TAT specific cytotoxic T-cells for preventi will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1903682